

# SARC Semiannual Meeting Agenda

Friday, June 1, 2018

8:00	Opening Remarks	
8:05	Chawla-Rosenfeld Developmental Therapeutics Symposium	
	Introduction: Epigenetics and Osteosarcoma	David Kirsch, MD, PhD Robert Maki, MD, PhD
	Mutant p53 Gain-of-Function in Osteosarcoma Metastasis	Shunbin Xiong, PhD
	Targeting the metastatic epigenome of osteosarcoma	Peter Scacheri, PhD
	Genome informed targeted therapy for osteosarcoma	Marcus Breese, PhD
	Osteosarcoma: The Transition from Empiricism to Precision Medicine	Richard Gorlick, MD
	<i>Discussion/Q&amp;A</i>	Panel
9:50	Break	
10:10	Demonstration Projects	
	Demonstration Project Grants	David Kirsch, MD, PhD
	Development of a Circulating Tumor DNA Assay for Leiomyosarcoma	Brian Crompton, MD
	Evaluating outcome of patients with refractory MPNST enrolled on phase 2 trials conducted by SARC	Srivandan Akshintala, MBBS, MPH
	SARC Unified Data System: Biospecimens, Data and Imaging	Rachel Luchs SARC Lead Project Manager
10:40	Career Development Program	
	2018 Award Announcement	Elizabeth Lawlor, MD, PhD
10:50	Sarcoma Patient Advocacy Coalition	
	Bringing Advocates Together	Annie Achee Peter Wyckoff
11:05	SARC Clinical Trials	
	Introductions	Scott Okuno, MD
	SARC024: Phase 2 trial of regorafenib in refractory selected subtypes of sarcomas	Robert Maki, MD, PhD Richard Riedel, MD Christopher Ryan, MD Lara Davis, MD Steven Attia, DO Leo Mascarenhas, MD
	SARC028: Phase 2 trial of the anti-PD1 antibody pembrolizumab (MK-3475) in patients with advanced sarcomas	Hussein Tawbi, MD, PhD Melissa Burgess, MD
	SARC031: Phase 2 Trial of the MEK inhibitor selumetinib (AZD6244 hydrogen sulfate) in combination with the dual mTOR kinase inhibitor vistusertib (AZD2014) for patients with unresectable or metastatic malignant peripheral nerve sheath tumors	AeRang Kim, MD, PhD Brigitte Widemann, MD
	SU2C-SARC032-SPORE05: Phase 2 Randomized Controlled Trial of Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity	David Kirsch, MD, PhD Yvonne Mowery, MD, PhD Richard Riedel, MD Brian Brigman, MD PhD
	SARC033-SPORE06 ETCTN NCI Protocol #10015: Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma	Scott Schuetze, MD, PhD
12:00	Adjourn	

# THANK YOU

**SARC gratefully acknowledges the following supporters:**

## *Platinum Level*



## *Gold Level*



## *Silver Level*



If you are interested in learning more about funding levels and how to support SARC, please feel free to contact SARC directly.

Email: [sarc@sarc\\_trials.org](mailto:sarc@sarc_trials.org) or 734-930-7600



**SARC**  
collaborating to cure sarcoma

24 FRANK LLOYD WRIGHT DRIVE  
LOBBY A, SUITE 3100  
ANN ARBOR, MICHIGAN 48105

PHONE: 734.930.7600  
FAX: 734.930.7557  
SARC TRIALS.ORG